BRPI0508333A - uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit - Google Patents

uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit

Info

Publication number
BRPI0508333A
BRPI0508333A BRPI0508333-8A BRPI0508333A BRPI0508333A BR PI0508333 A BRPI0508333 A BR PI0508333A BR PI0508333 A BRPI0508333 A BR PI0508333A BR PI0508333 A BRPI0508333 A BR PI0508333A
Authority
BR
Brazil
Prior art keywords
compound
vitamin
interstitial cystitis
kit
preventing
Prior art date
Application number
BRPI0508333-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0404571A external-priority patent/GB0404571D0/en
Priority claimed from GB0404567A external-priority patent/GB0404567D0/en
Priority claimed from PCT/US2004/031532 external-priority patent/WO2005030223A1/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of BRPI0508333A publication Critical patent/BRPI0508333A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0508333-8A 2004-03-01 2005-03-01 uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit BRPI0508333A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0404571A GB0404571D0 (en) 2004-03-01 2004-03-01 Methods for treating interstitial cystitis and related compounds and compositions
GB0404567A GB0404567D0 (en) 2004-03-01 2004-03-01 Methods for treating bladder dysfunction and related compounds and compositions
PCT/US2004/031532 WO2005030223A1 (en) 2003-09-24 2004-09-24 Methods for treating bladder dysfunction
PCT/EP2005/050902 WO2005082375A2 (en) 2004-03-01 2005-03-01 Treatment of interstitial cystitis with vitamin d compounds

Publications (1)

Publication Number Publication Date
BRPI0508333A true BRPI0508333A (pt) 2007-07-17

Family

ID=34915952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508333-8A BRPI0508333A (pt) 2004-03-01 2005-03-01 uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit

Country Status (7)

Country Link
US (1) US20080039434A1 (enExample)
EP (1) EP1737468A2 (enExample)
JP (1) JP2007525533A (enExample)
AU (1) AU2005216651A1 (enExample)
BR (1) BRPI0508333A (enExample)
CA (1) CA2557809A1 (enExample)
WO (1) WO2005082375A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318911A1 (en) * 2004-09-24 2008-12-25 Bioxell S.P.A. 20-Cyclopropyl, 26,27-Alkyl/Haloalkyl Vitamin D3 Compounds and Methods of Use Thereof
RU2423972C1 (ru) * 2009-12-16 2011-07-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ консервативного лечения гиперактивного мочевого пузыря у детей с учетом его суточной активности
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9877929B2 (en) 2011-10-13 2018-01-30 Premier Dental Products Company Topical vitamin D and ubiquinol oral supplement compositions
CN104968351A (zh) * 2012-10-12 2015-10-07 第一牙科产品公司 局部用的维生素d口腔补充组合物
US9877930B2 (en) 2012-10-12 2018-01-30 Premier Dental Products Company Topical ubiquinol oral supplement compositions with amorphous calcium phosphate
US9724542B2 (en) 2012-10-12 2017-08-08 Premier Dental Products Company Remineralizing and desensitizing compositions, treatments and methods of manufacture
CN104758300A (zh) * 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
RU2602954C1 (ru) * 2015-07-27 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской Федерации Средство для лечения хронических воспалительных заболеваний уретры и мочевого пузыря
WO2017147420A1 (en) * 2016-02-25 2017-08-31 The University Of Florida Research Foundation, Inc. Methods and compositions with vitamin d compounds for treatment of cystic fibrosis and respiratory disorders
MX2019006008A (es) 2016-11-23 2019-12-11 Huawei Tech Co Ltd Sistema de red optica pasiva, terminal de linea optica y unidad de red optica.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639596A (en) 1969-07-14 1972-02-01 Wisconsin Alumni Res Found Method of treating leg weakness in fowl with 25-hydroxycholecalciferol
US3739001A (en) 1971-10-22 1973-06-12 Wisconsin Alumni Res Found 25,26-dihydroxycholecalciferol
US3741996A (en) 1971-12-02 1973-06-26 Wisconsin Alumni Res Found 1{60 -hydroxycholecalciferol
US3715374A (en) 1972-05-05 1973-02-06 Wisconsin Alumni Res Found 24,25-dihydroxycholecalciferol
US3847955A (en) 1973-07-16 1974-11-12 Wisconsin Alumni Res Found 1,24,25-trihydroxycholecalciferol
JPS5126859A (en) 1974-08-22 1976-03-05 Teijin Ltd 24 * r * hidorokishikorekarushifuerooruno seizoho
JPS5126858A (en) 1974-08-22 1976-03-05 Teijin Ltd 24 * s * hidorokishikorekarushifuerooruno seizoho
JPS5271456A (en) 1975-12-12 1977-06-14 Chugai Pharmaceut Co Ltd Synthesis of 1alpha-hydroxysteroid derivatives
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4927815A (en) * 1988-04-29 1990-05-22 Wisconsin Alumni Research Foundation Compounds effective in inducing cell differentiation and process for preparing same
US4847012A (en) 1988-04-29 1989-07-11 Wisconsin Alumni Research Foundation Vitamin D related compounds and processes for their preparation
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
US5312328A (en) * 1991-01-11 1994-05-17 Baxter International Inc. Ultra-sound catheter for removing obstructions from tubular anatomical structures such as blood vessels
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
CA2096105A1 (en) 1992-10-07 1994-04-08 Enrico Giuseppe Baggiolini (Deceased) Vitamin d3 fluorinated analogs
US5428029A (en) 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
KR100327922B1 (ko) 1995-09-21 2002-05-09 리차드 에이취 리저 칼시트리올유도체및그의용도
SG70009A1 (en) 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
US5939408A (en) 1996-05-23 1999-08-17 Hoffman-La Roche Inc. Vitamin D3 analogs
BR9809313B1 (pt) 1997-04-28 2010-11-16 compostos análogos de vitamina d3, processo para a sua preparação e utilização dos mesmos para a preparação de medicamentos para o tratamento de hiperparatiroidismo primário e secundário, osteodistrofia renal, doenças de auto imunização, esclerose múltipla ou lúpus, e doenças neoplásticas.
US6030962A (en) 1997-04-28 2000-02-29 Synttex (U.S.A.) Inc. Vitamin D3 analogs with bis C-20 side chains
FR2763328B1 (fr) 1997-05-14 1999-07-02 Vetrotex France Sa Procede de production de fils de verre ensimes et produits resultants
AU743514B2 (en) 1997-05-16 2002-01-24 Women & Infants Hospital Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof
CA2288710A1 (en) 1997-05-16 1998-11-19 Women & Infants Hospital 3-epi vitamin d2 compounds and uses thereof
US20020045606A1 (en) 1999-12-02 2002-04-18 Reddy Satyanarayana G. Esters of vitamin D3 and uses thereof
US20010034328A1 (en) * 2000-02-25 2001-10-25 Cartt Stephen Lahue Treatment of male chronic pelvic pain syndrome
WO2004098612A2 (en) 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2005030223A1 (en) * 2003-09-24 2005-04-07 Bioxell, S.P.A. Methods for treating bladder dysfunction

Also Published As

Publication number Publication date
JP2007525533A (ja) 2007-09-06
US20080039434A1 (en) 2008-02-14
WO2005082375A2 (en) 2005-09-09
CA2557809A1 (en) 2005-09-09
EP1737468A2 (en) 2007-01-03
WO2005082375A3 (en) 2005-10-13
AU2005216651A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
CO2022000270A2 (es) Inhibidores de enzimas
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
BR0213317A (pt) Uso de um composto, método de tratar um distúrbio relacionado com gastrina, composição farmacêutica, kit, usos de uma composição, e de um inibidor de bomba de próton, métodos de preparar uma composição farmacêutica e um composto, e, composto
PT1220676E (pt) Prevencao do cancro colorrectal

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.